Bengaluru, June 26 -- During Thursday's trading session, the shares of a global pharmaceutical company providing access to affordable and innovative medicines tumbled by nearly 2 percent on BSE, after CITI Research trimmed target price and recommended a "sell" rating on the stock, with a downside of about 25 percent.

With a market capitalisation of Rs. 1.09 lakh crores, at 11:26 a.m., the shares of Dr Reddy's Laboratories Limited were trading in the red at Rs. 1.317.6 on BSE, down by 1.7 percent, as compared to its previous closing price of Rs. 1,340.85. The stock has delivered positive returns of nearly 9 percent in the last one year, and has gained by over 6 percent in a month.

Brokerage Target & Outlook Global brokerage firm CITI Res...